Table 1.
Clinical studies investigating the role of PLR in predicting cancer patient outcomes.
| Reference | Cancer type | # of patients | Range cutoffs (survival) | Multivariate HR (OS) | Time of measurement |
|---|---|---|---|---|---|
| Wang et al. (39) | Prostate | 290 | PLR > 117.58 | 1.65, p = 0.044 | Diagnosis |
| Yu et al. (40) | Non-small cell lung | 210 | PLR > 152.6 | 2.03, p < 0.001 | Pretreatment |
| Krenn-Pilko et al. (41) | Breast | 793 | PLR > 292 | 1.92, p = 0.047 | Preoperative |
| Raungkaewmanee et al. (42) | Epithelial ovarian | 166 | PLR > 200 | NS | Preoperative |
| Ozawa et al. (43) | Colorectal | 234 | PLR > 25.4 | CSS—3.61, p = 0.038 | Preoperative |
| Szkandera et al. (20) | Colon | 372 | PLR > 224 | NS | Preoperative |
| Smith et al. (44) | Pancreatic ductal adenocarcinoma | 110 | PLR > 150 | 1.00, p = 0.003 | Preoperative |
CSS, cancer-specific survival; NS, not significant; OS, overall survival.